Marek Kulus

Omalizumab for asthma in adults and children

Secondhand smoke in combination with ambient air pollution exposure is associated with increasedx CpG methylation and decreased expression of IFN-γ in T effector cells and Foxp3 in T regulatory cells in children

Adult-onset asthma: is it really different?

Moving towards precision care for childhood asthma

Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma

Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children

Asthma

Correlations between basophil activation, allergen-specific IgE with outcome and severity of oral food challenges

Pharmacological treatment of severe, therapy-resistant asthma in children: what can we learn from where?

mRNA transcript therapy

Asthma phenotypes: the evolution from clinical to molecular approaches

Current status of therapy with omalizumab in children

Outdoor air pollution and asthma

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management

Exploring the Effects of Omalizumab in Allergic Asthma

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)

British Guideline on the Management of Asthma

Risks Related to the Use of Non-Steroidal Anti-Inflammatory Drugs in Community-Acquired Pneumonia in Adult and Pediatric Patients

Parental tobacco smoking is associated with augmented IL-13 secretion in children with allergic asthma

Basophil activation test based on the expression of CD203c in the diagnostics of cow milk allergy in children

Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma

Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma

Risk factors for local complications in children with community‐acquired pneumonia